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MATERIALS AND METHODS

Subjects
Family J. The father in this family was previously identified because of the abnormal electrophoretic mobility of his plasma and platelet A subunits. Although this subject has reduced factor XI11 activity in plasma, he is clinically normal. Initial studies suggested that this subject was heterozygous for a variant, unstable A subunit umbilicus on separation of the cord 8 days after birth and had her first blood transfusion. She was always covered in bruises as soon as she started to walk and had numerous bleeding episodes from the gums and mouth during teething. Minor injury to her left wrist at the age of 4 years resulted in a huge hematoma that required several weeks to resolve. After being hit on the head by a swing at the age of 10 years, a hematoma on the forehead required 5 weeks to resolve. D.S. suffered severe backache, probably due to bleeding into the muscles in the region of the loin and pelvic girdle. She consequently spent many months on orthopedic traction and could not walk for a long time. Diagnosis of factor XI11 deficiency was made at the age of 10 years. Plasma factor XI11 activity was zero with the dansylcadaverine-casein assay. No A-subunit protein could be detected in the plasma by immunoelectrophoresis. B-subunit protein levels were 47% of our standard normal pooled plasma. In 1972 D.S. started prophylaxis with fresh frozen plasma given every 6 weeks. Since 1973. she has been treated with the Hoechst placental factor XI11 concentrate (Hoechst, Marburg, Germany). She has not had any bleeding manifestations since and leads a normal active life. She has gone through two pregnancies successfully and remains well on regular prophylaxis with the factor XI11 concentrate.
L.S. is a female who was born in 1961. She bled from the umbilicus a few days after birth and was always covered in bruises as soon as she started to walk. L.S. had severe bleeding from the gums after she developed a dental abscess and had to be transfused with 2 U of blood. At the age of 8 years, she had extensive and very painful bruising of the chest, left loin area, and left hip region. This occurred without any obvious trauma. She was given a 3-U blood transfusion, and the bruising slowly resolved. Diagnosis of factor XI11 deficiency was established when the patient was 8.5 years old. Plasma factor XI11 activity was zero with the dansylcadaverine-casein assay. No A-subunit protein could be detected in the plasma by immunoelectrophoresis. B-subunit protein levels were 48% of our standard normal pooled plasma. In 1972, L.S. started regular prophylaxis with fresh frozen plasma. In 1977, she commenced therapy with the Hoechst factor XI11 concentrate. Bleeding manifestations are completely controlled. She has gone through three pregnancies successfully, leads a normal and active life, and remains well on regular prophylaxis with the factor XI11 concentrate.
Identijication of Mutations
Amplification of the 15 exons encoding the A subunit was performed by the polymerase chain reaction (PCR) with the primers and conditions previously described in detaiL7 Amplified exons from each subject were subjected to heteroduplex analysis on 8% and 10% polyacrylamide gel^.'^^'^ Those exons exhibiting the formation of heteroduplexes were cloned in M13mp18 and sequenced by the dideoxy chain termination method.I4 In each case, multiple clones were sequenced to be sure of identifying the mutation in heterozygotes. Where a mutation was identified, it was confirmed by sequencing products from a separate amplification experiment and by examination of family members.
Construction of Mutant cDNAs and Expression of Recombinant A Subunits
A full-length F'XIIIA subunit cDNA'' was cloned in M13mp19, and single-stranded DNA was used as a template for oligonucleotidedirected mutagenesis. Mutations detected in the coding sequence of genomic DNA from patients with A-subunit deficiency were inserted in cDNA clones. The mutagenesis was performed using a kit supplied by Amersham (Sydney, Australia) (RPN 1523). The oligonucleotides used to create the mutations are shown in Table 1 . In each case, an additional mutation was made to add or delete a closely linked restriction site that allowed final confirmation that the correct construct was ultimately transferred to the yeast expression vector. The inclusion of these additional diagnostic mutations did not change the encoded amino acid sequence of the cDNA. The initial success of the mutagenesis was confirmed by nucleotide sequencing. The double-stranded replicative form of the mutated M13 clones was subsequently purified, and fragments of cDNA containing mutations were excised with appropriate restriction enzymes and ligated into the A-subunit cDNA in a yeast expression vector, as shown schematically in Fig 1. Plasmid pRB334 contains the normal FXIIIA cDNA, pN60K contains the FXIIIA cDNA with the N60K mutation, and pG501R contains the FXIIIA cDNA with the G501R mutation.
In these constructs, the last (Gly76) codon of ubiquitin is followed by a codon for the mature FXIIIA amino-terminal residue serine. Cleavage of ubiquitin from ubiquitin-fusion proteins is accomplished by endogenous ubiquitin-specific proteases" and, in this instance, exposes serine at the N-terminus of FXIIIA. Expression of proteins as fusions to ubiquitin has been reported to enhance their yield in yeast, and cleavage of ubiquitin occurs very rapidly, perhaps ~otranslationally.'~.'~ Immunoblot analysis with FXIIIA antiserum (Behringwerke AG, Marburg, Germany) detected a protein with the expected molecular weight for FXIIIA, indicating that cleavage of ubiquitin from the fusion protein had occurred (see Fig 3) . No intact fusion protein was observed.
Saccharomyces cerevisiae AH22 expressing recombinant A subunits from either pRB334, pN60K, or pG5OIR were lysed by vortexing with glass beadsM in a lysing solution containing 50 mmoI/ L HEPES pH 7.5, 150 mmol/L NaCl, 5 mmoVL EDTA, 1% Triton X100, 0.1 mmoVL phenylmethylsulphonyl fluoride, and S mmol/L P-mercaptoethanol
Characterization of FXlllA
The transglutaminase activity of activated A subunits was determined by measuring the incorporation of I4C putrescine into dimethylcasein, as previously described." This assay contained 33 mmoV L dithiothreitol to ensure that the active site cystein was not oxidized. The qualitative evaluation of A-subunit expression in yeast extracts and in fractions eluted from fast protein liquid chromatography (FPLC) gel filtration columns was performed by observing the incorporation of monodansyl cadaverine into casein by a fluorescent spot technique.''
The pH optimum was determined by evaluating activity in the presence of buffers covering the pH range from 6 to 11.5.*' The stability of the mutant A subunits was evaluated by observing the decay of activity during exposure to 55°C. Because preliminary studies indicated that the Gly 501 + Arg mutation lost activity during storage and purification, the determination of pH optimum and heat stability was performed in fresh yeast lysates.
To determine if the recombinant mutant A subunits formed a normal dimeric complex, the elution volume of mutant A subunits was compared with the elution volume of normal recombinant A 
RESULTS
Mutation Analysis
Family S. Heteroduplex analysis of the amplified FXI-IIA exons from family S indicated the presence of sequence differences in exons 3 and 11. These exons were cloned in M13mp18 and sequenced. The mutation in exon 3 was found to be a C + A transversion that alters codon 60 from AAC to AAA. This mutation results in the substitution Asn60 Lys. The mutation in exon 11 was found to be a C + A transversion that alters codon 4 4 1 from TAC to TAA. This mutation results in the substitution of Tyr 4 4 1 -t stop and would prematurely terminate translation. The genetic transmission of these mutations was demonstrated in the family as shown in Fig 2. The exon 3 mutation is clearly inherited from the maternal parent, and the exon 11 mutation is inherited from the paternal parent.
Family J. Heteroduplex analysis indicated that exon 12 from the father contained a sequence abnormality. This exon was cloned in M 13mpI 8 and sequenced. The mutation in exon 12 was found to be a G + A transition that changes codon 501 from GGA to AGA. This mutation results in the substitution Gly 501 + Arg. The genetic transmission of this mutation was confirmed by an analysis of DNA from the proband's daughter (Fig 2) .
Expression of Mutant FXIIIA Subunits
The mutations that cause amino acid substitutions in exons 3 and 12 were engineered in the FXIIIA cDNA and incorporated in the yeast expression vector pRB334 as shown in Fig 1. The level of factor XI11 activity in crude lysates of fresh yeast cultures expressing these mutant subunits is shown in Table 2 . No activity could be detected in the sample expressing the exon 3 Am60 + Lys mutation. In contrast, substantial activity was detected in cultures expressing A subunit with the exon 12 Gly501 + Arg substitution. However, it was noted that the activity expressed by this mutation diminished during storage of the sample compared with identically stored wild-type extracts.
Immunoblots of extracts fractionated by SDS-PAGE showed that abundant amounts of A subunit were expressed in cultures containing the wild-type cDNA (pRB334) and cultures expressing the exon 12 GlyS01 + Arg substitution (Fig 3) . In each case, the recombinant A subunits were the same size as A subunits derived from platelets. In some experiments, there appeared to be a trace of A subunit detectable in the cultures with the exon 3 Am60 + Lys substitution; however, this is not visible in Fig 3. To determine if FXIIIA mRNA was transcribed from the construct with the As1160 + Lys substitution, we performed a Northern blot experiment. As shown in Fig 4, FXIIIA mRNA of the same size and approximate quantity was present in the yeast expressing the normal A subunit (pRB334) or either of the two mutated forms (pGSOIR. pN60K). These data indicate that the C + A mutation causing the Asn60 -t Lys substitution does not destabilize the mRNA and suggest that the newly synthesized protein is very unstable and/or the subject of increased proteolytic degradation.
Clmracterization of the GIy.501 + Arg Mutant Subunit Although fresh cultures expressing A subunit with the GlyS01 + Arg substitution have high catalytic activity, attempts to purify this protein were frustrated by a loss of activity during storage and purification procedures. This instability is clearly shown in Fig S. Heating the crude extracts at 55°C results in a rapid total loss of activity in the Gly501 + Arg sample compared with the normal enzyme, which is only slightly decreased over the same time period. The GlyS01 + Arg substitution results in a charge change of + 1. This change confers a slower native electrophoretic mobility on the recombinant isoenzyme (Fig 6) , as was originally observed in the proband." We considered that the charge change may directly influence the active site, and this may be reflected in a change in the pH optimum. However, a comparison of the normal and GlyS01 + Arg enzyme activities at different pH levels showed a pH optimum of 8.5 in each case and essentially identical activity/pH profiles (data not shown).
We also considered the possibility that the Gly SO1 + Arg substitution may affect the formation of homodimers. Gel filtration studies on an FPLC Superose 12 column indicated that the recombinant normal and Gly S01 + Arg-substituted enzymes are eluted in identical volumes (data not shown). This result indicates that the variant has a dimeric structure identical to that of the normal enzyme.
DISCUSSION
The present studies have identified three mutations in the FXIIIA subunit genes in two families. In family S, both affected children have a severe deficiency of A subunit as a result of inheriting a mutation causing premature termination of translation at codon 4 4 1 from the paternal parent and an amino acid substitution (Asn 60 + Lys) from the maternal parent. It has previously been very difficult, if not impossible, to characterize abnormal A subunits in deficient patients. The difficulties include the occurrence of normal A subunits in the plasma of patients provided with replacement therapy, the probable existence of compound heterozygotes who express two different mutant forms of A subunit, and the extremely low levels of residual A subunit in patients, such as the two children in family S. Some of these problems can now be circumvented by the expression of recombinant A subunits in microbial systems. We have previously demonstrated the expression of functional FXIIIA in Escherichia coli"; however, the yields from this procedure are not as great as those obtained in yeast.'" Therefore, we have used a yeast expression system that can produce significant quan- For personal use only. on August 30, 2017. by guest www.bloodjournal.org From tities of A subunit that has been mutated to include the individual substitutions detected in patients. In the case of family S, the Asn60 + lays mutation results in the expression of a protein that is extremely unstable and/or is the subject of rapid proteolytic degradation. This conclusion is supported by the observation that mRNA encoding this mutation is readily detectable in yeast containing the recombinant construct. Thus. in this particular case and despite the use of yeast expression technology, we were unable to obtain sufficient protein to allow any characterization.
In contrast, the expression of A subunit with the GIy501 + Arg substitution detected in family J has allowed more extensive characterization of the protein. Members of this family with the mutation are heterozygotes and do not show any clinical symptoms. We originally detected individuals with this variant because of its slow native electrophoretic mobility in agarose gels." The variant subunit was termed type 3, and its slow electrophoretic mobility suggested that it may result from an amino acid substitution that increased the net charge on the protein. This observation has been confirmed, as the Gly + Arg substitution gives a charge change of + 1 and the electrophoretic mobility of the recombinant mutant enzyme is electrophoretically slow.
Our earlier studies of this variant suggested that the mutant subunit was unstable and had an elevated pH optimum." The recombinant Gly501 + Arg mutant A subunit shows marked instability on storage and under heat treatment; how-" I \ ever, we found no evidence for a shift in its pH optimum. This difference from our previous results may reflect the different origins of the material studied in each experiment. In our earlier experiments, we measured activity in plasma from heterozygotes expressing the type 1 and type 3 (Gly501 -+ Arg) subunits. In these samples, there was no evidence for type 3 homodimers, and the activity attributable to the type 3 subunit was probably contributed by the type 3 subunit in a heterodimeric combination with type 1 subunits. In the present investigation, we are studying a homodimer, and it is possible that the previously observed difference in the pH optimum results from the interaction of dissimilar subunits. Alternatively, as the original experiments were performed with plasma that contained B subunits, a differential interaction between the Gly 501 + Lys A subunits and the B subunits cannot be excluded. The possibility that different posttranslational modifications could also influence the pH response should also be considered.
These studies suggest that although heterozygotes in family J are unaffected by this mutation, it would cause clinical deficiency in the homozygous form or in combination with another deleterious mutation. Several different mutations causing FXIIIA deficiency have been described in this and previous st~dies.""' Clearly, insufficient numbers of cases have been studied to determine the degree of genetic heterogeneity in this disease. Considerably more cases will need to be studied in different racial groups to determine if particular mutations are common in specific populations, as clearly occurs in Finland."
Little is known about the structure/function relationships of the A-subunit protein and its interaction with the B subunit. The expression of mutants in yeast and characterization of A subunits initially identified in deficient patients have the potential to identify areas of the A-subunit molecule involved in particular functions and can be used to gain a greater understanding of structure/function relationships.
